January 21, 2022 -- Eikonoklastes Therapeutics has completed a license agreement with the University of California, San Diego to add a novel gene therapy for the treatment of neurodegenerative diseases, including a potential treatment for Lou Gehrig's disease, or amyotrophic lateral sclerosis.
Eikonoklastes completed a series A financing round in the second quarter of 2021. The company was founded to rapidly advance breakthrough technologies, starting with a novel fusion protein for the treatment of triple-negative breast cancer. Eikonoklastes has engineered molecules that attack three key components of the tumor microenvironment by activating the body's natural immune system without harming normal cells, according to the company.
Financial details of the agreement were not disclosed.
Copyright © 2022 scienceboard.net